SCHEMBL13590125

SCHEMBL13590125

CN(C)CCOc1ccc(CCN2CCC(C(C(N)=O)(c3ccccc3)c3ccccc3)C2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACKR3 P25106 4/20 0.59
▸ KCNH2 Q12809 2/20 0.57
▸ CHRM3 P20309 2/20 0.57
▸ ADRB2 P07550 1/20 0.57
▸ CHRM2 P08172 1/20 0.57
▸ CHRM4 P08173 1/20 0.57
▸ ADRB1 P08588 1/20 0.57
▸ CHRM5 P08912 1/20 0.57
▸ ADRA2A P08913 1/20 0.57
▸ CHRM1 P11229 1/20 0.57
▸ DRD2 P14416 1/20 0.57
▸ KCNE1 P15382 1/20 0.57
▸ ADRA2B P18089 1/20 0.57
▸ ADRA2C P18825 1/20 0.57
▸ HRH2 P25021 1/20 0.57
▸ HTR2A P28223 1/20 0.57
▸ SLC6A4 P31645 1/20 0.57
▸ ADRA1A P35348 1/20 0.57
▸ OPRM1 P35372 1/20 0.57
▸ OPRK1 P41145 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4431523 0.90 OPRM1 (0.62) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL4431527 0.90 OPRM1 (0.62) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL13590474 0.85 ACKR3 (0.59) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL10868089 0.85 OPRM1 (0.57) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL13590127 0.84 ACKR3 (0.56) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL13590529 0.84 ACKR3 (0.66) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL9361710 0.84 ACKR3 (0.75) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL9361705 0.84 ACKR3 (0.75) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL9361499 0.84 CHRM3 (0.69) ACKR3KCNH2CHRM3ADRB2CHRM2
SCHEMBL9361492 0.84 CHRM3 (0.69) ACKR3KCNH2CHRM3ADRB2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 — — US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306134-A1 Muscarinic receptor antagonists CHRM3, CHRM5, CHRM2 ACKR3 191/4885KCNH2 1070/4885CHRM3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback